{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:15:28Z","timestamp":1785503728863,"version":"3.56.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Antibody-induced complement activation may cause injury of the neuromuscular junction (NMJ) and is thus considered as a primary pathogenic factor in human myasthenia gravis (MG) and animal models of experimental autoimmune myasthenia gravis (EAMG). In this study, we tested whether CRIg\/FH, a targeted complement inhibitor, could attenuate NMJ injury in rat MG models. We first demonstrated that CRIg\/FH could inhibit complement-dependent cytotoxicity on human rhabdomyosarcoma TE671 cells induced by MG patient-derived IgG<jats:italic>in vitro<\/jats:italic>. Furthermore, we investigated the therapeutic effect of CRIg\/FH in a passive and an active EAMG rodent model. In both models, administration of CRIg\/FH could significantly reduce the complement-mediated end-plate damage and suppress the development of EAMG. In the active EAMG model, we also found that CRIg\/FH treatment remarkably reduced the serum concentration of autoantibodies and of the cytokines including IFN-\u03b3, IL-2, IL-6, and IL-17, and upregulated the percentage of Treg cells in the spleen, which was further verified<jats:italic>in vitro<\/jats:italic>. Therefore, our findings indicate that CRIg\/FH may hold the potential for the treatment of MG<jats:italic>via<\/jats:italic>immune modulation.<\/jats:p>","DOI":"10.3389\/fimmu.2022.746068","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T04:38:39Z","timestamp":1643171919000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A Targeted Complement Inhibitor CRIg\/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation"],"prefix":"10.3389","volume":"13","author":[{"given":"Jie","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00257","article-title":"Complement System Part II: Role in Immunity","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1124\/pharmrev.120.000072","article-title":"Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics","volume":"73","author":"Garred","year":"2021","journal-title":"Pharmacol Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement System Part I - Molecular Mechanisms of Activation and Regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1305","article-title":"The Central Role of the Alternative Complement Pathway in Human Disease","volume":"176","author":"Thurman","year":"2006","journal-title":"J Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.molimm.2015.03.011","article-title":"Of Mice and Men: The Factor H Protein Family and Complement Regulation","volume":"67","author":"Pouw","year":"2015","journal-title":"Mol Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nature05263","article-title":"Structure of C3b in Complex With CRIg Gives Insights Into Regulation of Complement Activation","volume":"444","author":"Wiesmann","year":"2006","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.12.039","article-title":"CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens","volume":"124","author":"Helmy","year":"2006","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1096\/fj.14-258046","article-title":"A Novel CRIg-Targeted Complement Inhibitor Protects Cells From Complement Damage","volume":"28","author":"Qiao","year":"2014","journal-title":"FASEB J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800987","article-title":"Complement Inhibitor CRIg\/FH Ameliorates Renal Ischemia Reperfusion Injury via Activation of PI3K\/AKT Signaling","volume":"201","author":"Hu","year":"2018","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12882-019-1599-0","article-title":"The New Complement Inhibitor CRIg\/FH Ameliorates Lupus Nephritis in Lupus-Prone MRL\/lpr Mice","volume":"20","author":"Shi","year":"2019","journal-title":"BMC Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26695","article-title":"Cross-Sectional Analysis of the Myasthenia Gravis Patient Registry: Disability and Treatment","volume":"60","author":"Cutter","year":"2019","journal-title":"Muscle Nerve"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia Gravis - Autoantibody Characteristics and Their Implications for Therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement Inhibitor Therapy for Myasthenia Gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and Efficacy of Eculizumab in Anti-Acetylcholine Receptor Antibody-Positive Refractory Generalised Myasthenia Gravis (REGAIN): A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011207","article-title":"Post-Intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension","volume":"96","author":"Mantegazza","year":"2021","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical Effects of the Self-Administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.5407","article-title":"Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis: A Randomized Clinical Trial","volume":"78","author":"Sharshar","year":"2021","journal-title":"JAMA Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.expneurol.2015.02.025","article-title":"Guidelines for Pre-Clinical Assessment of the Acetylcholine Receptor\u2013Specific Passive Transfer Myasthenia Gravis Model-Recommendations for Methods and Experimental Designs","volume":"270","author":"Kusner","year":"2015","journal-title":"Exp Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.expneurol.2015.03.010","article-title":"Standardization of the Experimental Autoimmune Myasthenia Gravis (EAMG) Model by Immunization of Rats With Torpedo Californica Acetylcholine Receptors\u2013Recommendations for Methods and Experimental Designs","volume":"270","author":"Losen","year":"2015","journal-title":"Exp Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.4.2697","article-title":"Breakdown of Tolerance to a Self-Peptide of Acetylcholine Receptor Alpha-Subunit Induces Experimental Myasthenia Gravis in Rats","volume":"172","author":"Baggi","year":"2004","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-019-1687-x","article-title":"CXCR5-Negative Natural Killer Cells Ameliorate Experimental Autoimmune Myasthenia Gravis by Suppressing Follicular Helper T Cells","volume":"16","author":"Yang","year":"2019","journal-title":"J Neuroinflamm"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401392","article-title":"Antigen-Specific Immunotherapeutic Vaccine for Experimental Autoimmune Myasthenia Gravis","volume":"193","author":"Luo","year":"2014","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ar.22641","article-title":"Quantitative Analysis of Histological Staining and Fluorescence Using ImageJ","volume":"296","author":"Jensen","year":"2013","journal-title":"Anat Rec (Hoboken)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13591","article-title":"An Imbalance Between Regulatory T Cells and T Helper 17 Cells in Acetylcholine Receptor-Positive Myasthenia Gravis Patients","volume":"1413","author":"Villegas","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.05.006","article-title":"Inhibition of ROCK Activity Regulates the Balance of Th1, Th17 and Treg Cells in Myasthenia Gravis","volume":"203","author":"Song","year":"2019","journal-title":"Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.7.3526","article-title":"Expression of Human Complement Receptor Type 2 (CD21) in Mice During Early B Cell Development Results in a Reduction in Mature B Cells and Hypogammaglobulinemia","volume":"169","author":"Marchbank","year":"2002","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01607","article-title":"Complement Factor H Modulates Splenic B Cell Development and Limits Autoantibody Production","volume":"10","author":"Kiss","year":"2019","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302484","article-title":"Cholesterol Crystals Induce Complement-Dependent Inflammasome Activation and Cytokine Release","volume":"192","author":"Samstad","year":"2014","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.070166","article-title":"The Role of Complement in Inflammatory Diseases From Behind the Scenes Into the Spotlight","volume":"171","author":"Markiewski","year":"2007","journal-title":"Am J Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.10.5941","article-title":"Effects of Cytokines on Acetylcholine Receptor Expression: Implications for Myasthenia Gravis","volume":"174","author":"Poea-Guyon","year":"2005","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22070","article-title":"Increased Serum Interleukin-17 Levels in Patients With Myasthenia Gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00809","article-title":"CD4(+) T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17a Productions and Higher Presence of PD-1 and ICOS","volume":"11","author":"Cebi","year":"2020","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106130","article-title":"Comparison of Peripheral Blood B Cell Subset Ratios and B Cell-Related Cytokine Levels Between Ocular and Generalized Myasthenia Gravis","volume":"80","author":"Hu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12974-017-0892-8","article-title":"Regulatory T Cells in Multiple Sclerosis and Myasthenia Gravis","volume":"14","author":"Danikowski","year":"2017","journal-title":"J Neuroinflamm"},{"key":"B35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1749-6632.2012.06840.x","article-title":"Functional Defect in Regulatory T Cells in Myasthenia Gravis","volume":"1274","author":"Thiruppathi","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2499","article-title":"Absence of Signaling Into CD4(+) Cells via C3aR and C5aR Enables Autoinductive TGF-Beta1 Signaling and Induction of Foxp3(+) Regulatory T Cells","volume":"14","author":"Strainic","year":"2013","journal-title":"Nat Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500455","article-title":"The Complement Inhibitor Factor H Generates an Anti-Inflammatory and Tolerogenic State in Monocyte-Derived Dendritic Cells","volume":"196","author":"Olivar","year":"2016","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e29540","DOI":"10.7554\/eLife.29540","article-title":"CRIg, a Tissue-Resident Macrophage Specific Immune Checkpoint Molecule, Promotes Immunological Tolerance in NOD Mice, via a Dual Role in Effector and Regulatory T Cells","volume":"6","author":"Yuan","year":"2017","journal-title":"Elife"},{"key":"B39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.imlet.2015.04.004","article-title":"Endogenous VSIG4 Negatively Regulates the Helper T Cell-Mediated Antibody Response","volume":"165","author":"Jung","year":"2015","journal-title":"Immunol Lett"},{"key":"B40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia Gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of Myasthenia Gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23247","article-title":"Protective Effect of scFv-DAF Fusion Protein on the Complement Attack to Acetylcholine Receptor: A Possible Option for Treatment of Myasthenia Gravis","volume":"45","author":"Song","year":"2012","journal-title":"Muscle Nerve"},{"key":"B43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaut.2013.01.003","article-title":"Complement C2 siRNA Mediated Therapy of Myasthenia Gravis in Mice","volume":"42","author":"Huda","year":"2013","journal-title":"J Autoimmun"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.142.8.2654","article-title":"Inhibition of Acute Passive Transfer Experimental Autoimmune Myasthenia Gravis With Fab Antibody to Complement C6","volume":"142","author":"Biesecker","year":"1989","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25673","article-title":"VSIG4, a B7 Family-Related Protein, is a Negative Regulator of T Cell Activation","volume":"116","author":"Vogt","year":"2006","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1021\/bi4003452","article-title":"Functional Anatomy of Complement Factor H","volume":"52","author":"Makou","year":"2013","journal-title":"Biochemistry"},{"key":"B47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/biom2010046","article-title":"Factor H: A Complement Regulator in Health and Disease, and a Mediator of Cellular Interactions","volume":"2","author":"Kopp","year":"2012","journal-title":"Biomolecules"},{"key":"B48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel Complement Inhibitor Limits Severity of Experimentally Myasthenia Gravis","volume":"65","author":"Soltys","year":"2009","journal-title":"Ann Neurol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.9.4522","article-title":"Humoral Immune Responses in Cr2-\/- Mice: Enhanced Affinity Maturation But Impaired Antibody Persistence","volume":"164","author":"Chen","year":"2000","journal-title":"J Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242569","article-title":"IL-17-Producing Gammadelta T Cells and Innate Lymphoid Cells","volume":"42","author":"Sutton","year":"2012","journal-title":"Eur J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.746068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T19:56:57Z","timestamp":1674590217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.746068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2022.746068"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.746068","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]},"article-number":"746068"}}